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ABSTRACT: In this paper, we describe the discovery and optimization of a new chemotype of
isoform selective PI3Kγ inhibitors. Starting from an HTS hit, potency and physicochemical
properties could be improved to give compounds such as 15, which is a potent and remarkably
selective PI3Kγ inhibitor with ADME properties suitable for oral administration. Compound 15
was advanced into in vivo studies showing dose-dependent inhibition of LPS-induced airway
neutrophilia in rats when administered orally.
■ INTRODUCTION
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases whose
primary function is to catalyze phosphorylation of the 3-
position of the inositol ring of membrane phosphoinositides.
This initiates a complex downstream signaling network that
regulates cell growth, survival, migration, and proliferation. The
PI3K family is clustered into three diﬀerent classes (classes I, II,
and III) based on structural features and substrate preference.
Class I consists of four isoforms (α, β, γ, and δ). It is by far the
most extensively studied of the PI3K classes and has been an
attractive target for the pharmaceutical industry over the past
decade. The PI3Kγ isoform is primarily found in leukocytes and
is a key regulator of cellular migration.1,2 A PI3Kγ inhibitor
could thus potentially be used to treat a variety of diseases in
which inﬂux of inﬂammatory eﬀector cells plays a key role in
pathology, including diseases within the areas of respiratory and
inﬂammation, metabolic disorders, and cancer.3−5 Unfortu-
nately, highly selective PI3Kγ inhibitors are rare as it has been
diﬃcult to identify truly isoenzyme selective compounds due to
the high sequence homology between the PI3K isoforms. From
a safety perspective, high isoform selectivity is essential as
PI3Kα has been shown to aﬀect glucose and insulin signaling.6
It has also been shown that PI3Kγ knockout mice are viable and
fertile while genetic inactivation of PI3Kα or -β results in
embryonic lethality.7,8 Recently compounds with high γ isoform
selectivity have been reported, including IPI-549 which is
currently in clinical trials in immuno-oncology applications.9−11
We now report our discovery of a series of highly selective
PI3Kγ inhibitors. This series, which was identiﬁed in a HTS,
contains an isoindolinone core that extends deep into the ATP-
binding pocket and utilizes a selectivity switch that has not been
previously described for PI3K inhibitors.
■ RESULTS AND DISCUSSION
Our eﬀorts to discover selective PI3Kγ inhibitors with suitable
ADME properties for oral dosing started with a full HTS of our
corporate screening collection using a biochemical enzyme
inhibition assay for PI3Kγ. This was followed by a counter-
screen for PI3Kα in order to identify series with some inherent
PI3Kγ selectivity. One hit series contained an isoindolinone
core (Figure 1). Compound 1 was one of the most potent in
this cluster and exhibited high selectivity toward PI3Kα. It was
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Figure 1. Isoindolinone containing HTS hit 1 identiﬁed as an inhibitor
of PI3Kγ and methylated analogue 2.
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proﬁled in a PI3Kγ target engagement cell assay measuring
phosphorylation of AKT but was inactive at 1 μM.12
The attractive selectivity proﬁle meant that this series was
still deemed to be of interest. It was not immediately apparent
what binding mode the compounds might have in the PI3Kγ
enzyme, and we made repeated eﬀorts to crystallize compounds
from this series with a PI3Kγ construct to guide further design
but without success. This was surprising since PI3Kγ has been
shown to be very amenable to crystallization and has often been
used as a surrogate for the other class 1 PI3Ks;13 at
AstraZeneca our in-house database contains more than 80
PI3Kγ structures. We screened near neighbors of 1 to build a
picture of the SAR. Compound 2, a methylated matched-pair
analogue of 1, lost signiﬁcant PI3Kγ activity (Figure 1). This
prompted us to hypothesize that the acetamido-substituted
isoxazole might interact with the hinge region of the kinase.
Even though isoxazole is not a common hinge-binding motif, it
does contain a hydrogen bond donor/acceptor pair typical for
kinase inhibitors. The dependence of activity on the donor NH
suggested this could be a good place to start exploring SAR.
A set of amino heterocycles that are typical kinase hinge-
binding motifs were therefore introduced to replace the
isoxazole (Table 1). Encouragingly, several of these such as
aminopyrimidine 3 and pyrrolopyrazine 5 were potent
inhibitors of PI3Kγ, supporting the hypothesis that this part
of the molecule was interacting with the hinge. This was further
strengthened with data for compounds 6−10 which all carried
hinge-binding motifs that had been used in previously reported
PI3Kγ inhibitors.6,14,15 The introduction of an aminothiazole
heterocycle in 7−10 gave a marked increase in enzyme
potency, and to our delight this was also reﬂected in the data
from the cell assay showing pIC50 of 7−8 (Table 1). These
results clearly supported the hypothesis that this part of the
molecule was binding to the hinge region, but we were still
unable to crystallize these more potent compounds in our
PI3Kγ construct.
Table 1. Structure, PI3K Enzyme and Cell Inhibitory Potencies, and Pharmacokinetically Relevant Properties of Compounds
3−10a
aAll biological values are the mean of ≥3 replicates except ‡n = 2, †n = 1. bCompound 10, which is also depicted above, is the R-enantiomer. cNT,
not tested. dIntrinsic clearance in rat hepatocytes ((μL/min)/106 cells).
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Compounds 3−10 all showed very good selectivity toward
the other class I isoforms. Compound 9, however, was a
moderately potent inhibitor of PI3Kδ, and we therefore
investigated crystallization in a PI3Kδ construct. Rewardingly,
this was successful, and crystals of 9 in mouse PI3Kδ could be
obtained (Figure 2). The structure conﬁrms that the amino-
thiazole heterocycle is interacting with the hinge residues as
bidentate hydrogen bonds to Val828 are observed. The
isoindolinone core forms hydrophobic interactions with
Ile825 and the carbonyl of the lactam hydrogen-bonds with
the catalytic Lys779. All these interactions are made with
residues that are conserved between all four isoforms and do
not give any clue to the high isoform selectivity observed in this
series. However, one feature that is unique in this series is the
N-alkyl tail, which is oriented perpendicular to the
isoindolinone core, positioning the cyclopropyl ring close to
Met788 and the methyl close to Asp787, both residues that
form part of the kα3-helix (the equivalent to αC-helix in
protein kinases). This observation prompted further inves-
tigation of the N-alkyl substituent, and a set of analogues was
prepared. However, out of the 80 compounds prepared in this
set no compound had increased potency compared to the
original methylcyclopropyl moiety that originated from the
HTS hit (data not shown). The stereochemistry did not have a
large impact on selectivity or potency as the (R)-stereoisomer
10 had similar potency in the biochemical assay to the (S)-
stereoisomer 8 but was slightly less potent in the cell assay
(Table 1). More interesting results were obtained when
removing the alkyl group from the nitrogen altogether giving
compound 11 (Table 2).
Comparison of the matched-pair analogues 9 and 11 showed
a dramatic 2 log drop in PI3Kγ potency, while PI3Kα potency
increased by 1.6 log. Interestingly, PI3Kδ potency was hardly
aﬀected and PI3Kβ potency increased but less dramatically than
α. The remarkable PI3Kγ selectivity thus seems to originate
from the N-alkyl tail extending deep into the ATP-binding
pocket and pushing on the kα3-helix. Comparison of the
obtained structure with PI3Kγ-structures of reported selective
inhibitors shows that this is a unique feature of this series as
none of the reported inhibitors extend as far into the ATP-
binding pocket (Figure S1, Supporting Information).
It is important to remember that the crystal structure of 9 is
in murine PI3Kδ and thus may not reveal all structural details
relevant to understanding the high PI3Kγ selectivity. Com-
pound 9 was proﬁled in a panel of 132 kinases at 1 μM
(Thermo Fisher). Approximately 100% inhibition was observed
for PI3Kγ and also for DRAK1, while greater than 50%
inhibition was observed for CLK4 and PI3Kδ (Table S1,
Supporting Information). The pIC50 values of 9 against
DRAK1, and CLK4 were determined and show that even
though 9 has a good kinase selectivity proﬁle it is also a potent
inhibitor of DRAK1 and CLK4 with pIC50 values of 8.0 and 6.9,
respectively. The most potent compounds 8 and 9 did not have
a suitable proﬁle for oral administration as they had poor
solubility, high in vitro clearance and were very lipophilic. To
improve ADME properties, design was focused on reducing
lipophilicity. It has been shown that sulfonamides,6 reversed
sulfonamides,16 and sulfones17 can be introduced in the ribose
pocket of PI3Ks; overlay of the crystal structure of 9 with the
public structure of PIK-93 (PDB code 2CHZ),6 suggested that
it could be possible to target the ribose pocket from the
isoindolinone core by substitution on the 7-position (Figure 3).
This was judged to be a good position to introduce more polar
functionalities to decrease lipophilicity. Sulfonamides 12−14,
sulfones 15 and 16, and reversed sulfonamides 17 and 18
Figure 2. X-ray crystal structure of compound 9 in mouse PI3Kδ
(PDB code 6FTN). The aminothiazole forms hydrogen bonds to the
hinge residue Val828. The carbonyl of the lactam interacts with
Lys779. The N-alkyl tail is oriented perpendicular to the isoindolinone
core and is extending deep into the ATP-binding pocket.
Table 2. PI3K Enzyme and Cell Inhibitory Potencies for 9
and the Matched-Pair Analogue 11a
pIC50
compd PI3Kγ enz PI3Kα enz PI3Kβ enz PI3Kδ enz PI3Kγ cell
9 9.2 5.5 4.7 6.7 8.2
11 7.2 7.1‡ 5.8‡ 6.6‡ <6.0†
aAll biological values are mean of ≥3 replicates except ‡n = 2, †n = 1.
Figure 3. X-ray crystal structure of compound 9 in mouse PI3Kδ
(ligand in green, protein in gray, PDB code 6FTN) overlaid with
structure of literature compound PIK-93 in PI3Kγ (ligand in yellow,
protein in blue, PDB code 2CHZ).6
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extending from the 7-position of the isoindolinone core were
prepared. The majority of these compounds had maintained or
increased PI3Kγ potency while at the same time having a lower
log D (Table 3). The most potent compounds in the enzymatic
and cellular assay were N-methylsulfonamide 13, methyl
sulfone 15, and reversed methylsulfonamides 17 and 18.
Compound 18, however, exhibited high intrinsic clearance in
rat hepatocytes. Compounds 13, 15, and 17 were selected for
further proﬁling.
All the shortlisted compounds, 13, 15, and 17, showed
excellent isoform selectivity in the biochemical assays, and this
proﬁle was also conﬁrmed in mechanism-based cellular assays
measuring phosphorylation of AKT. The compounds showed
high activity in the PI3Kγ target engagement cell assay and
>100-fold selectivity in a human Jeko-1B cell line that assesses
PI3Kδ activity (Table 4). The compounds were inactive in two
other cell assays: a human MDA MB-468 cell line and a human
BT4 cell line that assess activity of PI3Kα and PI3Kβ,
respectively. Compound 15 had considerably better kinetic
solubility than 13 and 17 (Table 3). The diﬀerence was less
pronounced when thermodynamic solubility at pH 6.5 was
measured, but 15 was still the most soluble (Table 4). The
compounds had a clear margin against inhibition of the hERG
channel and also for general cytotoxicity assessed in THP1 cells
and HepG2 cells. In vitro PK data of the three compounds
showed that 15 consistently had the lowest intrinsic clearance
and highest free fraction across three species (human, rat, and
dog). In vivo, 17 showed low clearance in rat and had the
longest half-life of the shortlisted compounds in this species.
Also in dog, 17 had a lower clearance than predicted from in
vitro data, but in this species in vivo clearance was the highest
among the three compounds. In addition, bioavailability of 17
in dog was only 1.6%. Compound 15 on the other hand had
good bioavailability and low clearance in both species which
was consistent with in vitro data. On the basis of these data, 15
was identiﬁed as the compound with the best proﬁle for oral
administration and was chosen for further proﬁling. Kinase
selectivity proﬁling of 15 at 1 μM in a panel of 395 kinases
(Thermo Fisher) including protein and lipid kinases showed
excellent kinase selectivity (Table S2, Supporting Information),
and no activity could be detected for the previously observed
oﬀ-targets DRAK1 and CLK4.
Except for PI3Kγ (95%) and -δ (66%) the only kinases that
showed greater than 50% inhibition at 1 μM were the class II
PI3Ks: PI3KC2β (84%) and PI3KC2γ (71%). Thus, to get a
more complete view of the selectivity toward class II and class
III PI3Ks, pIC50 values of 15 against all class II and class III
PI3Ks were determined (Table 5). These data showed that 15
Table 3. Structure, PI3K Enzyme and Cell Inhibitory Potencies, and Pharmacokinetically Relevant Properties of Compounds
12−18a
pIC50
compd R PI3Kγ enz PI3Kα enz PI3Kβ enz PI3Kδ enz PI3Kγ cell log D, pH 7.4 sol, pH 7.4 (μM) rat Clint
b
12 -SO2NH2 9.2 5.2
‡ <4.5‡ 6.6 7.7‡ 2.5 8 <2
13 -SO2NHMe 9.1 5.4 4.6 6.8 8.3 3.0 4 5
14 -SO2NH(CH2)2OMe 8.9 4.9
‡ <4.5‡ 6.4‡ 7.7† 2.7 61 56
15 -SO2Me 9.1 5.1 <4.5 6.5 8.1 2.4 303 <2
16 -SO2(CH2)3OH 8.9 5.1
‡ <4.5‡ 6.7‡ 6.6† 1.9 463 6
17 -NHSO2Me 9.2 5.2
‡ 4.7‡ 6.6 8.6 3.3 <1 4
18 -NHSO2(CH2)2OMe 9.0 5.3
‡ 4.6‡ 6.6‡ 8.2† 3.5 14 166
aAll biological values are the mean of ≥3 replicates except ‡n = 2, †n = 1. bIntrinsic clearance in rat hepatocytes ((μL/min)/106 cells).
Table 4. Selected Properties of Compounds 13, 15, and 17
property 13 15 17
PI3Kγ cell pIC50 8.3 8.1 8.6
PI3K α/β/δ cell pIC50 <4.5/<4.5/6.4 <4.5/<4.5/6.0 <4.5/<4.5/6.1
aq solubility pH 6.5 (μM) 9 111 5
hERG pIC50 <4.5 4.5 4.7
cytotoxicity THP1 pIC50 3.8 4.1 4.7
mitochondrial toxicity not active not active not active
PPB human/rat/dog (% free) 9/8/10 12/12/22 1/1/5
hepatocyte Clint human/rat/dog ((μL/min)/10
6 cells) 0.5/4.5/2.1 0.4/1.7/1.0 3.4/3.7/7.6
in vivo PK
rat Cl ((mL/min)/kg), t1/2 (h), F (%), Vss (L/kg) 4.4, 2.6, 30, 1.0 6.3, 2.3, 51, 1.2 0.7, 6.7, 49, 0.4
dog Cl ((mL/min)/kg), t1/2 (h), F (%), Vss (L/kg) 2.1, 12, 44, 2.2 3.3, 3.9, 82, 1.1 6.2, 1.3, 1.6, 0.7
Table 5. Selectivity Proﬁling of Compound 15 toward Class
II and Class III PI3Ksa
pIC50
PI3Kγ enz PI3KC2α enz PI3KC2β enz PI3KC2γ enz PI3KC3 enz
>9.2b <5 7.5 5.5 5.1
aAll biological values are the mean of ≥2 replicates. bThe exact pIC50
could not be determined in this assay format.
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inhibits the class II PI3K PI3KC2β with a pIC50 of 7.5 as
compared to a pIC50 > 9.2 for PI3Kγ in a comparable
biochemical assay. Relatively little is known about the role of
class II PI3Ks,18 and no notable activity of 15 was recorded for
the other class II and class III PI3Ks.
Compound 15 was also screened in a wide ligand proﬁle
screen (CEREP), covering 89 distinct molecular targets (Table
S4, Supporting Information). Compound 15 showed good
selectivity margins, with only one target, P2Y1, with a Ki below
1 μM. Follow-up screening showed no activity (<100 μM) of
15 as agonist or antagonist in whole cell P2Y1 assays. On the
basis of the encouraging pharmacokinetic and safety/selectivity
proﬁle of 15, we decided to progress into a rat LPS-induced
acute inﬂammation model, measuring airway neutrophilia.
Compound 15 was dosed 2 h prior to challenge and inhibited
neutrophil migration with a dose-response over doses of 0.1,
0.5, and 2.5 mg/kg (Figure 4). These data strongly suggest that
oral administration of 15 inhibits PI3Kγ function in vivo.
Compound 15 was prepared in four steps starting from a
methylester derivative that was reacted with (S)-1-cyclopropyl-
ethanamine to give isoindolinone 19 (Scheme 1). The
aminothiazole was introduced by a Pd-catalyzed coupling of
isoindolinone 19 with N-(4-methylthiazol-2-yl)acetamide. This
was followed by an SNAr reaction with sodium methanthiolate
to give the intermediate sulﬁde which could be oxidized to the
desired sulfone 15 by using m-CPBA.
■ CONCLUSION
A series of highly isoform-selective PI3Kγ inhibitors have been
developed starting from a high quality HTS hit. This series,
which contains an alkyl-substituted isoindolinone core, exhibits
remarkable isoform selectivity which originates from the N-
alkyl tail extending deep into the ATP-binding pocket. The
initial hit was eﬃciently progressed by use of structure based
design to more advanced compounds, e.g., 15. This compound
combines high biochemical and cellular potency with excellent
isoform selectivity and has an attractive pharmacokinetic and in
vitro safety proﬁle. Oral administration of 15 resulted in a dose-
dependent inhibition of LPS-induced airway neutrophilia in
rats.
■ EXPERIMENTAL SECTION
All compounds were puriﬁed to ≥95% purity (HPLC). Further
synthetic details and full descriptions of biological methods are
contained in the Supporting Information.
N-(5-{7-Chloro-2-[(1S)-1-cyclopropylethyl]-1-oxo-2,3-dihy-
dro-1H-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)acetamide (8).
Cs2CO3 (37.3 g, 114 mmol) was added to a ﬂask containing 19
(18.0 g, 57 mmol), N-(4-methyl-1,3-thiazol-2-yl)acetamide (10.7 g, 69
mmol), tri-tert-butylphosphonium tetraﬂuoroborate (3.3 g, 11 mmol),
and Pd(OAc)2 (1.3 g, 6 mmol) in DMF (300 mL). The resulting
mixture was heated at 100 °C. After 2 h it was cooled to rt, ﬁltered
through Celite, and concentrated. The residue was chromatographed
(silica gel; 0−25% of MeOH in DCM) to aﬀord the title compound
(14.0 g, 63%) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ
0.2−0.27 (m, 1H), 0.35−0.43 (m, 2H), 0.52−0.61 (m, 1H), 1.08−1.14
(m, 1H), 1.28 (d, J = 6.8 Hz, 3H), 2.16 (s, 3H), 2.40 (s, 3H), 3.52−
3.63 (m, 1H), 4.56 (s, 2H), 7.50 (s, 1H), 7.64 (s, 1H), 12.23 (s, 1H).
HRMS: m/z calcd 390.1043, found 390.1022.
N-(5-{2-[(1S)-1-Cyclopropylethyl]-7-(methylsulfonyl)-1-oxo-
2,3-dihydro-1H-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)-
acetamide (15). Sodium methanethiolate (5.0 g, 71 mmol) was
added to 8 in DMF (80 mL). The resulting mixture was heated at 110
°C for 2 h. The solvent was removed under reduced pressure, and the
reaction mixture was poured into water. The resulting precipitate was
collected by ﬁltration, washed with water (200 mL) and EtOAc (50
mL), and dried under vacuum to aﬀord the intermediate sulﬁde (4.10
g, 72%), which was used in the next step (below) without further
puriﬁcation.
m-CPBA (3.3 g, 19.3 mmol) was added to the sulﬁde prepared
above (3.1 g, 7.7 mmol) in DCM (120 mL). The resulting mixture was
stirred at 0 °C for 1 h, then warmed to rt and stirred for 1 h. The
reaction mixture was quenched with saturated NaHCO3 (200 mL) and
extracted with DCM. The organic layer was dried over Na2SO4,
ﬁltered, and concentrated. The crude product was puriﬁed by
preparative HPLC to aﬀord the title compound 15 (1.2 g, 36%) as
a white solid. 1H NMR (500 MHz, DMSO-d6) δ 0.24−0.29 (m, 1H),
0.38−0.46 (m, 2H), 0.57−0.62 (m, 1H), 1.11−1.19 (m, 1H), 1.31 (d, J
= 6.8 Hz, 3H), 2.17 (s, 3H), 2.44 (s, 3H), 3.59−3.65 (m, 4H), 4.70 (s,
Figure 4. Eﬀect of compound 15 on LPS-induced neutrophil
migration in rats. LPS challenged Wistar females were dosed po
with 15 2 h prior to challenge. 4 h after challenge the animals were
sacriﬁced. Lung ﬂuid was collected by lavage, and diﬀerential cell count
was performed using a SYSMEX XT-1800i. Neutrophil migration was
signiﬁcantly inhibited in a dose-dependent manner with 15. n = 8 in all
groups (n = 10 for vehicle group). Statistical signiﬁcance is indicated as
follows above the columns: (∗) p < 0.001; (∗∗∗) p < 0.05.
Scheme 1. Synthesis of Compound 15a
aReagents and conditions: (i) (S)-1-cyclopropylethanamine, B(OH)3, K2CO3, MeCN, 80 °C, 34%; (ii) N-(4-methylthiazol-2-yl)acetamide,
Pd(OAc)2, [(t-Bu)3PH]BF4, Cs2CO3, DMF, 100 °C, 63%; (iii) (a) NaSMe, DMF, 110 °C, 72%, (b) m-CPBA, DCM, 0 °C, 36%.
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2H), 8.00 (d, J = 1.5 Hz, 1H), 8.05 (d, J = 1.5 Hz, 1H), 12.30 (s, 1H).
13C NMR (126 MHz, DMSO-d6) δ 3.4, 3.9, 15.5, 16.3, 18.0, 22.5, 43.1,
45.9, 52.1, 121.8, 126.6, 127.3, 127.7, 135.4, 137.7, 144.6, 145.9, 156.3,
163.6, 168.7. [α]D +60 (c 1 g/100 mL, MeCN, 20 °C). HRMS: m/z
calcd 434.1208, found 434.1201.
5-Bromo-7-chloro-2-[(1S)-1-cyclopropylethyl]-2,3-dihydro-
1H-isoindol-1-one (19). (S)-1-Cyclopropylethanamine (2.4 mL, 23
mmol) was added to a ﬂask containing methyl 4-bromo-2-
(bromomethyl)-6-chlorobenzoate (7.8 g, 23 mmol) in acetonitrile
(80 mL). Boric acid (1.4 g, 23 mmol) was added, followed by
portionwise addition of K2CO3 (6.3 g, 46 mmol) over 2 min. The
mixture was allowed to stir at rt overnight. The reaction mixture was
ﬁltered and washed with acetonitrile. The combined acetonitrile
ﬁltrates were concentrated and the residue was chromatographed
(silica gel; 5−30% of EtOAc in heptane) to aﬀord the title compound
(2.4 g, 34%) as a pink solid. 1H NMR (500 MHz, DMSO-d6) δ 0.15−
0.26 (m, 1H), 0.32−0.45 (m, 2H), 0.51−0.61 (m, 1H), 1.06−1.14 (m,
1H), 1.26 (d, J = 6.8 Hz, 3H), 3.48−3.58 (m, 1H), 4.52 (s, 2H), 7.76
(d, J = 1.3 Hz, 1H), 7.84 (d, J = 1.3 Hz, 1H). m/z (ESI) 316 [M +
H]+.
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